Cargando…

Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone

Therapies that target cancer cells may have unexpected effects on the tumor microenvironment that affects therapy outcomes or render therapy resistance. Prostate cancer (PCa) bone metastasis is uniquely associated with osteoblastic bone lesions and treatment with cabozantinib, a VEGFR-2 and MET inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Kai-Jie, Li, Jeffrey K., Lee, Yu-Chen, Yu, Guoyu, Lin, Song-Chang, Pan, Tianhong, Satcher, Robert L., Titus, Mark A., Yu-Lee, Li-Yuan, Weng, Wen Hui, Gallick, Gary E., Lin, Sue-Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650395/ https://www.ncbi.nlm.nih.gov/pubmed/29088840 http://dx.doi.org/10.18632/oncotarget.20489

Ejemplares similares

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation()()
por: Pan, Tianhong, et al.
Publicado: (2017)

Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4
por: Yu, Guoyu, et al.
Publicado: (2021)

Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone
por: Pan, Tianhong, et al.
Publicado: (2021)

Cadherin-11 in Renal Cell Carcinoma Bone Metastasis
por: Satcher, Robert L., et al.
Publicado: (2014)

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2020)

Bone secreted factors induce cellular quiescence in prostate cancer cells
por: Yu-Lee, Li-Yuan, et al.
Publicado: (2019)

Endothelial-to-osteoblast transition in normal mouse bone development
por: Lin, Song-Chang, et al.
Publicado: (2023)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
por: Kumar, Shreya, et al.
Publicado: (2023)

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
por: Fioramonti, Marco, et al.
Publicado: (2017)

The osteoblast secretome in Staphylococcus aureus osteomyelitis
por: Granata, Valentina, et al.
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway
por: Zeng, Hao, et al.
Publicado: (2016)

Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition
por: Lee, Yu-Chen, et al.
Publicado: (2022)

Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells
por: Chatterji, Tanushree, et al.
Publicado: (2015)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?
por: Farach-Carson, Mary C., et al.
Publicado: (2017)

Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis
por: Jin, Jung-Kang, et al.
Publicado: (2014)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Secretome analysis of rat osteoblasts during icariin treatment induced osteogenesis
por: Qian, Weiqing, et al.
Publicado: (2018)

The Lymphatic Endothelial Cell Secretome Inhibits Osteoblast Differentiation and Bone Formation
por: Solorzano, Ernesto, et al.
Publicado: (2023)

Local Liver Irradiation Concurrently Versus Sequentially with Cabozantinib on the Pharmacokinetics and Biodistribution in Rats
por: Huang, Yu-Chuen, et al.
Publicado: (2023)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction
por: Sun, Sheng, et al.
Publicado: (2015)

ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction
por: Sun, Sheng, et al.
Publicado: (2016)

Endothelial Cells as Precursors for Osteoblasts in the Metastatic Prostate Cancer Bone
por: Paiva, Ana E., et al.
Publicado: (2017)

Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
por: Su, Kuan-Wei, et al.
Publicado: (2021)

Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer
por: Schaffer, Elisabeth M, et al.
Publicado: (2021)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_99a4ne3m2d9f5ce9r1kd04tnnh